Last reviewed · How we verify
Kanglaite Injection plus gemcitabine
At a glance
| Generic name | Kanglaite Injection plus gemcitabine |
|---|---|
| Also known as | KLT |
| Sponsor | KangLaiTe USA |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE4)
- Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kanglaite Injection plus gemcitabine CI brief — competitive landscape report
- Kanglaite Injection plus gemcitabine updates RSS · CI watch RSS
- KangLaiTe USA portfolio CI